Slide 1: AusBiotech 2013 "Brokers meet Biotech"
AusBiotech 2013 “Brokers meet Biotech” CALZADA LIMITED ASX:CZD September 2013
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation has been prepared by Calzada Limited and is provided for general information purposes only. No party other than Calzada has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings i
Slide 3: Calzada Limited
Calzada Limited Calzada LTD Directors ASX Code CZD David Franklyn Chairman Share Price 7.3 cents Bruce Rathie Non Exec. Issued Shares 406m David McQuillan Non Exec. Market Cap. $30 million Cash on Hand* $6.2 million Major Shareholders Merchant Funds 16% Management 8% Monash / Frank Ng 4% *Includes e
Slide 4: PolyNovo's biodegradable polymer technology, NovoSorb
PolyNovo’s biodegradable polymer technology, NovoSorbTM, has applications as a tissue scaffold and for use in reconstructive surgery.
Slide 5: The NovoSorb Technology
The NovoSorb™ Technology NovoSorbTM Foam Polymers Other Polymers TNP Dermal Pelvic Hernia Ortho- Cardio- Bone Void Drug Wound Replace- Floor Repair paedic vascular Fillers eluting Dressings ment Repair implants Stents coatings Facial Augment.
Slide 6: The NovoSorb Foam
The NovoSorb™ Foam • PolyNovo’s lead products are based around the NovoSorbTM biodegradable foam which has applications as a tissue scaffold in: Ø Burn and wound repair (BTM) Ø Wound dressings (TNP) Ø Hernia repair Ø Facial augmentation Ø Pelvic Floor repair Ø Etc. • Key attributes of the NovoSorbTM
Slide 7: How does it work ?
How does it work ? BTM in third degree burn Tissue integration at day 3 BTM fully integrated at day 10 Ready for skin grafting Skin graft on integrated BTM
Slide 8: Repair of a surgical wound – NovoSorb BTM
Repair of a surgical wound – NovoSorbTM BTM Day 0 post Day 0 (33.5cm2) BTM Implantation Day 5 (31.7cm2) Day 21 Day 21 Day 14 (35.6cm2) Post delamination Post grafting Six weeks post Three months Six months grafting (23.1cm2) post grafting post grafting
Slide 9: Repairing Surgical Wounds – with and without BTM
Repairing Surgical Wounds – with and without BTM Skin graft directly over Wound treated with wound – current treatment NovoSorb™ BTM foam
Slide 10: Commercial Progress
Commercial Progress Human Regulatory Commercialisation Market Trials US Size TNP foam Completed 510(k) Discussions ~$400M submitted underway Surgical Completed 510(k) Preliminary wounds submission discussions by Q1 2014 Burns Further PMA Preliminary ~$100M+ required discussions Hernia Partner 510(k)
Slide 11: Metabolic
INK. metabolic
Slide 12: What is AOD9604?
What is AOD9604? Burns fat, AOD9604 Inhibits storage Growth hormone fragment (only 8% of the GH molecule) Fat Direct cellular pathway IGF-1 pathway IGF-1 and pro-diabetic Promotes repair effects removed Cartilage 2nd hormone - IGF1 Bone & Muscle (made in the liver) Muscle and Protein Bone Organ synt
Slide 13: Commercialising AOD9604
Commercialising AOD9604 • Compounding Chemist licensing Ø AOD is legally available in Australia if prescribed by a Doctor and prepared by a compounding pharmacy Ø Metabolic investigating opportunity to license compounding chemists Ø Potential to deliver short term cash flow • Investigating Osteoarth